USA flag logo/image

An Official Website of the United States Government

SYNTHETIC OLIGONUCLEOTIDES FOR TRYPANOSOME CHEMOTHERAPY

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
7094
Program Year/Program:
1989 / SBIR
Agency Tracking Number:
7094
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Epoch Pharmaceuticals, Inc.
1725 220TH ST SE, 104 Bothell, WA 98052
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1989
Title: SYNTHETIC OLIGONUCLEOTIDES FOR TRYPANOSOME CHEMOTHERAPY
Agency: HHS
Contract: N/A
Award Amount: $490,442.00
 

Abstract:

THE 5' ENDS OF ALL TRYPANOSOME MRNAS HAVE RECENTLY BEEN SHOWN TO HAVE A COMMON 35-NUCLEOTIDE SPLICED LEADER (SL). THE SL IS BELIEVED TO ARISE BY TRANSCRIPTION WITHIN A MINI-EXON-DERIVED RNA (MEDRNA) OF ABOUT 140 NUCLEOTIDES, FOLLOWED BY ITS TRANS-SPLICING WITH THE PRIMARY TRANSCRIPTS OF MRNAS. THE PRESENCE OF THE SL IN ALL TRYPANOSOMAL MRNAS PROVIDES ANIDEAL SYSTEM TO TEST THE EFFICACY OF SHORT OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS. SYNTHETIC OLIGONUCLEOTIDES, CONSISTING OF DIESTERS, ETHYL PHOSPHOTRIESTERS, OR METHYL PHOSPHONATES, WILL BE SYNTHESIZED. THESE WILL BE COMPLEMENTARY TO THE SL SEQUENCE OR TO THE SPLICE-DONOR SITE OF THE MEDRNA TO DIRECTLY INHIBIT PROTEIN SYNTHESIS OR MRNA MATURATION. THESE OLIGONUCLEOTIDES WILL BE TESTED FOR THEIR ABILITY TO INHIBIT PROTEIN SYNTHESIS IN CELL-FREE SYSTEMS USING PURIFIED MRNA, AND IN CELL CULTURES OF TRYPANOSOMA BRUCEI. SPECIFIC ANTISENSE OLIGONUCLEOTIDES WILL PROVIDE VALUABLE CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF SIGNIFICANT HUMAN DISEASES.

Principal Investigator:

Dennis E Schwartz Phd
2064858566

Business Contact:

Small Business Information at Submission:

Microprobe Corp.
1725 220th St Southeast #104 Bothell, WA 98021

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No